Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pembrolizumab vs Placebo in Resected High-risk Stage II Melanoma (KEYNOTE-716)
2018-000669-35Phase 3Unknown
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Pembrolizumab adjuvant therapy with Placebo (2 arms). Primary endpoint: Recurrence-free survival (RFS). Status: unknown.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-000669-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000669-35.